NCT03915951 2025-11-17An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerPfizerPhase 2 Completed98 enrolled 18 charts 1 FDA
NCT03864042 2024-09-27Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid TumorsPfizerPhase 1 Completed56 enrolled 158 charts
NCT01543698 2024-03-13A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid TumorsPfizerPhase 1/2 Completed189 enrolled 44 charts
NCT02857270 2022-11-22A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerEli Lilly and CompanyPhase 1 Completed210 enrolled
NCT02278133 2017-10-09Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway MutationsArray BioPharmaPhase 1/2 Completed20 enrolled